2021 JAMA Oncology study finds many cancer drugs granted accelerated FDA approval show no significant benefits in survival or quality of life within 5 years.

A recent JAMA Oncology study reveals that most cancer drugs granted accelerated approval by the US FDA do not demonstrate significant benefits in overall survival or quality of life within five years after approval. The study highlights potential limitations in the accelerated approval process for cancer drugs and underlines the importance of continuous monitoring and evaluation of their long-term effects.